Eric Strain, MD
Psychiatry · Baltimore, MDNPI 1154356038
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,916 of the $15,089 with a category attached, or 85.6%. Eli Lilly accounts for 65.0% of it on its own, with 6 other manufacturers making up the rest. 2024 is the largest year on record at $9,811, 5.6 times the $1,758 reported in 2020. Among psychiatry clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 23 payments — averaging $656.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$10K
- Pear Therapeutics (US), Inc.$2K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
- Hikma Pharmaceuticals USA$794
- Dr.reddy's Laboratories,inc.$575
- Rhodes Pharmaceuticals L.p.$248
- plus $141 from 1 others
Across 7 payments — averaging $363.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Masimo Corporation$2K
- Teva Pharmaceuticals USA, Inc.$161
What the payments were for
- Consulting fees$12,91686%
- Speaking & faculty fees$951%
- Travel & lodging$1,92413%
- Food & beverage$1531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 10 | $9,811 |
| Pear Therapeutics (US), Inc. | 1 | $1,900 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,620 |
| Hikma Pharmaceuticals USA | 3 | $794 |
| Dr.reddy's Laboratories,inc. | 3 | $575 |
| Rhodes Pharmaceuticals L.p. | 1 | $248 |
| Mylan Inc. | 4 | $141 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$1,620
- Buprenorphine & Naloxone$740
- Buprenorphine$740
- Buprenorphine and Naloxone$536
How this compares
$15,089 in reported general payments places this provider in the 95th percentile of 851 psychiatry providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vilazodone Hcl | 12 | $1,259 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $572 |
| Divalproex Sodium ErDivalproex Sodium | 16 | $534 |
| Mirtazapine | 15 | $222 |
| Quetiapine Fumarate | 21 | $172 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $114 |
| Risperidone | 28 | $112 |
| Trazodone Hcl | 12 | $91 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Baltimore
- John VaethBaltimore$2.1M
- Scott AaronsonBaltimore$334K
- Robert LehmanBaltimore$140K
- Karen AndersonBaltimore$117K
- Orlando DavisBaltimore$104K
- Akira SawaBaltimore$69K
- Paul RosenbergBaltimore$66K
- Adam KaplinBaltimore$62K
- Marc FishmanBaltimore$59K
- David NeubauerBaltimore$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.